Merck & Co. (MRK): Our Calculation of Intrinsic Value

Key Takeaways

• Intrinsic value estimated at $96‑98, below $113 market price
• DCF uses 8% discount, 2% terminal growth rates
• Keytruda and vaccine pipeline drive cash flow growth
• Net debt stands at $34.7 billion, net of $14.6 billion cash
• Margin of safety negative ~14%, indicating modest overvaluation

Pulse Analysis

The discounted cash‑flow (DCF) approach applied to Merck underscores how valuation hinges on cash‑flow projections and discount assumptions. By using an 8% discount rate—reflective of the company’s weighted average cost of capital—and a modest 2% perpetual growth rate, the model yields a present value of roughly $273 billion for the enterprise. After accounting for $34.7 billion of net debt, the equity valuation translates to $96‑98 per share, noticeably lower than the current trading level. This spread highlights the sensitivity of pharma valuations to both macro‑economic inputs and company‑specific cash‑flow forecasts.

Merck’s growth narrative remains anchored by its flagship oncology drug Keytruda, which continues to expand across multiple indications and geographic markets. Complementary vaccine sales and a robust pipeline of biologics further bolster cash‑flow expectations. However, the company faces looming patent expirations on older products and intensifying competition from biosimilars, which could pressure future earnings if not offset by successful new launches or strategic acquisitions. The DCF model’s reliance on sustained pipeline success underscores the importance of R&D execution in maintaining Merck’s free‑cash‑flow trajectory.

From an investment standpoint, the modest overvaluation implied by the DCF suggests a cautious stance for equity holders. While Merck’s balance sheet remains strong—evidenced by $14.6 billion in cash against $49.3 billion of debt—investors must weigh the potential upside of continued Keytruda growth against the risk of patent cliffs and market saturation. Catalysts such as regulatory approvals, expansion into emerging markets, or strategic M&A could narrow the valuation gap, whereas setbacks in clinical trials may widen it. Consequently, the stock’s near‑term performance will likely reflect how effectively Merck navigates these dynamics while preserving its cash‑generation capacity.